These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 8793010)

  • 1. Complete inhibition of viral breakthrough by combination of MKC-442 with AZT during a long-term culture of HIV-1 infected cells.
    Okamoto M; Makino M; Yamada K; Nakade K; Yuasa S; Baba M
    Antiviral Res; 1996 Jun; 31(1-2):69-77. PubMed ID: 8793010
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The inhibition of human immunodeficiency virus type 1 in vitro by a non-nucleoside reverse transcriptase inhibitor MKC-442, alone and in combination with other anti-HIV compounds.
    Brennan TM; Taylor DL; Bridges CG; Leyda JP; Tyms AS
    Antiviral Res; 1995 Mar; 26(2):173-87. PubMed ID: 7541619
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Selective and synergistic inhibition of human immunodeficiency virus type 1 reverse transcriptase by a non-nucleoside inhibitor, MKC-442.
    Yuasa S; Sadakata Y; Takashima H; Sekiya K; Inouye N; Ubasawa M; Baba M
    Mol Pharmacol; 1993 Oct; 44(4):895-900. PubMed ID: 7694070
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Three-drug combination of MKC-442, lamivudine and zidovudine in vitro: potential approach towards effective chemotherapy against HIV-1.
    Piras G; Nakade K; Yuasa S; Baba M
    AIDS; 1997 Mar; 11(4):469-75. PubMed ID: 9084794
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preclinical evaluation of MKC-442, a highly potent and specific inhibitor of human immunodeficiency virus type 1 in vitro.
    Baba M; Shigeta S; Yuasa S; Takashima H; Sekiya K; Ubasawa M; Tanaka H; Miyasaka T; Walker RT; De Clercq E
    Antimicrob Agents Chemother; 1994 Apr; 38(4):688-92. PubMed ID: 7518216
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Patterns of resistance and cross-resistance to human immunodeficiency virus type 1 reverse transcriptase inhibitors in patients treated with the nonnucleoside reverse transcriptase inhibitor loviride.
    Miller V; de Béthune MP; Kober A; Stürmer M; Hertogs K; Pauwels R; Stoffels P; Staszewski S
    Antimicrob Agents Chemother; 1998 Dec; 42(12):3123-9. PubMed ID: 9835502
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Drug resistance and drug combination features of the human immunodeficiency virus inhibitor, BCH-10652 [(+/-)-2'-deoxy-3'-oxa-4'-thiocytidine, dOTC].
    Taylor DL; Ahmed PS; Tyms AS; Wood LJ; Kelly LA; Chambers P; Clarke J; Bedard J; Bowlin TL; Rando RF
    Antivir Chem Chemother; 2000 Jul; 11(4):291-301. PubMed ID: 10950391
    [TBL] [Abstract][Full Text] [Related]  

  • 8. N-[2-(1-cyclohexenyl)ethyl]-N'-[2-(5-bromopyridyl)]-thiourea and N'-[2-(1-cyclohexenyl)ethyl]-N'-[2-(5-chloropyridyl)]-thiourea as potent inhibitors of multidrug-resistant human immunodeficiency virus-1.
    Uckun FM; Mao C; Pendergrass S; Maher D; Zhu D; Tuel-Ahlgren L; Venkatachalam TK
    Bioorg Med Chem Lett; 1999 Sep; 9(18):2721-6. PubMed ID: 10509923
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Convergent combination therapy can select viable multidrug-resistant HIV-1 in vitro.
    Larder BA; Kellam P; Kemp SD
    Nature; 1993 Sep; 365(6445):451-3. PubMed ID: 7692302
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term exposure of HIV type 1-infected cell cultures to combinations of the novel quinoxaline GW420867X with lamivudine, abacavir, and a variety of nonnucleoside reverse transcriptase inhibitors.
    Balzarini J; De Clercq E; Carbonez A; Burt V; Kleim JP
    AIDS Res Hum Retroviruses; 2000 Apr; 16(6):517-28. PubMed ID: 10777142
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro evaluation of the effect of temporary removal of HIV drug pressure.
    Witvrouw M; Pannecouque C; Desmyter J; De Clercq E; Andries K
    Antiviral Res; 2000 Jun; 46(3):215-21. PubMed ID: 10867159
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of evolutionary limitations of HIV-1 multidrug resistance to optimize therapy.
    Chow YK; Hirsch MS; Merrill DP; Bechtel LJ; Eron JJ; Kaplan JC; D'Aquila RT
    Nature; 1993 Feb; 361(6413):650-4. PubMed ID: 7679778
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lamivudine resistance of HIV type 1 does not delay development of resistance to nonnucleoside HIV type 1-specific reverse transcriptase inhibitors as compared with wild-type HIV type 1.
    Jonckheere H; Witvrouw M; De Clercq E; Anné J
    AIDS Res Hum Retroviruses; 1998 Feb; 14(3):249-53. PubMed ID: 9491915
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Knocking-out concentrations of HIV-1-specific inhibitors completely suppress HIV-1 infection and prevent the emergence of drug-resistant virus.
    Balzarini J; Karlsson A; Pérez-Pérez MJ; Camarasa MJ; De Clercq E
    Virology; 1993 Oct; 196(2):576-85. PubMed ID: 7690501
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Lys103Asn mutation of HIV-1 RT: a novel mechanism of drug resistance.
    Hsiou Y; Ding J; Das K; Clark AD; Boyer PL; Lewi P; Janssen PA; Kleim JP; Rösner M; Hughes SH; Arnold E
    J Mol Biol; 2001 Jun; 309(2):437-45. PubMed ID: 11371163
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Drug combinations and effect parameters of zidovudine, stavudine, and nevirapine in standardized drug-sensitive and resistant HIV type 1 strains.
    Zhu QY; Scarborough A; Polsky B; Chou TC
    AIDS Res Hum Retroviruses; 1996 Apr; 12(6):507-17. PubMed ID: 8679306
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Perspectives of non-nucleoside reverse transcriptase inhibitors (NNRTIs) in the therapy of HIV-1 infection.
    De Clercq E
    Farmaco; 1999; 54(1-2):26-45. PubMed ID: 10321027
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthesis and evaluation of "AZT-HEPT", "AZT-pyridinone", and "ddC-HEPT" conjugates as inhibitors of HIV reverse transcriptase.
    Pontikis R; Dollé V; Guillaumel J; Dechaux E; Note R; Nguyen CH; Legraverend M; Bisagni E; Aubertin AM; Grierson DS; Monneret C
    J Med Chem; 2000 May; 43(10):1927-39. PubMed ID: 10821705
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Activity of non-nucleoside reverse transcriptase inhibitors against HIV-2 and SIV.
    Witvrouw M; Pannecouque C; Van Laethem K; Desmyter J; De Clercq E; Vandamme AM
    AIDS; 1999 Aug; 13(12):1477-83. PubMed ID: 10465070
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro comparison of selected triple-drug combinations for suppression of HIV-1 replication: the Inter-Company Collaboration Protocol.
    St Clair MH; Pennington KN; Rooney J; Barry DW
    J Acquir Immune Defic Syndr Hum Retrovirol; 1995; 10 Suppl 2():S83-91. PubMed ID: 7552518
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.